This complex pathology led to a controversy regarding which pathology (amyloid‐beta plaques, tau/p‐tau tangles, or cerebral amyloid angiopathy) is more critical in AD symptoms and therefore represents a better therapeutic target. Here, MAPT is linked to cerebral amyloid angiopathy.